|
1
|
Liu K, Chen HL, Wang S, Gu MM, Chen XM,
Zhang SL, Yu KJ and You QS: High expression of RIOK2 and NOB1
predict human non-small cell lung cancer outcomes. Sci Rep.
6:286662016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yang J, Lin J, Liu T, Chen T, Pan S, Huang
W and Li S: Analysis of lncRNA expression profiles in non-small
cell lung cancers (NSCLC) and their clinical subtypes. Lung Cancer.
85:110–115. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Torr LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tursz T, Andre F, Lazar V, Lacroix L and
Soria JC: Implications of personalized medicine-perspective from a
cancer center. Nat Rev Clin Oncol. 8:177–183. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Swanton C and Govindan R: Clinical
implications of genomic discoveries in lung cancer. N Engl J Med.
374:1864–1873. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Berge EM and Doebele RC: Targeted
therapies in non-small cell lung cancer: Emerging oncogene targets
following the success of epidermal growth factor receptor. Semin
Oncol. 41:110–125. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Travis WD, Brambilla E, Nicholson AG,
Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E,
Flieder DB, et al: The 2015 world health organization
classification of lung tumors: Impact of genetic, clinical and
radiologic advances since the 2004 classification. J Thorac Oncol.
10:1243–1260. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vargas AJ and Harris CC: Biomarker
development in the precision medicine era: Lung cancer as a case
study. Nat Rev Cancer. 16:525–537. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tsao AS, Scagliotti GV, Bunn PA Jr,
Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU,
McWilliams A, Tsao MS, et al: Scientific advances in lung cancer
2015. J Thorac Oncol. 11:613–638. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shyr D and Liu Q: Next generation
sequencing in cancer research and clinical application. Biol Proced
Online. 15:42013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gagan J and Van Allen EM: Next-generation
sequencing to guide cancer therapy. Genome Med. 7:802015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gerlinger M, Rowan AJ, Horswell S, Math M,
Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N,
Stewart A, et al: Intratumor heterogeneity and branched evolution
revealed by multiregion sequencing. N Engl J Med. 366:883–892.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kris MG, Johnson BE, Berry LD, Kwiatkowski
DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson
SL, Su PF, et al: Using multiplexed assays of oncogenic drivers in
lung cancers to select targeted drugs. JAMA. 311:1998–2006. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Crowley E, Di Nicolantonio F, Loupakis F
and Bardelli A: Liquid biopsy: Monitoring cancer-genetics in the
blood. Nat Rev Clin Oncol. 10:472–484. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bettegowda C, Sausen M, Leary RJ, Kinde I,
Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, et al:
Detection of circulating tumor DNA in early- and late-stage human
malignancies. Sci Transl Med. 6:224ra242014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hicks JK, Saller J, Wang E, Boyle T and
Gray JE: Cell-free circulating tumor DNA supplementing tissue
biopsies for identification of targetable mutations: Implications
for precision medicine and considerations for reconciling results.
Lung Cancer. 111:135–138. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xu S, Lou F, Wu Y, Sun DQ, Zhang JB, Chen
W, Ye H, Liu JH, Wei S, Zhao MY, et al: Circulating tumor DNA
identified by targeted sequencing in advanced-stage non-small cell
lung cancer patients. Cancer Lett. 370:324–331. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pisapia P, Pepe F, Smeraglio R, Russo M,
Rocco D, Sgariglia R, Nacchio M, De Luca C, Vigliar E, Bellevicine
C, et al: Cell free DNA analysis by SiRe® next
generation sequencing panel in non small cell lung cancer patients:
Focus on basal setting. J Thorac Dis. 9 (Suppl 13):S1383–S1390.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mayo-de-Las-Casas C, Jordana-Ariza N,
Garzón-Ibañez M, Balada-Bel A, Bertrán-Alamillo J, Viteri-Ramírez
S, Reguart N, Muñoz-Quintana MA, Lianes-Barragan P, Camps C, et al:
Large scale, prospective screening of EGFR mutations in the blood
of advanced NSCLC patients to guide treatment decisions. Ann Oncol.
28:2248–2255. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen K, Zhang J, Guan T, Yang F, Lou F,
Chen W, Zhao M, Zhang J, Chen S and Wang J: Comparison of plasma to
tissue DNA mutations in surgical patients with non-small cell lung
cancer. J Thorac Cardiovasc Surg. 154:1123–1131.e2. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kimura K and Koike A: Ultrafast SNP
analysis using the Burrows-Wheeler transform of short-read data.
Bioinformatics. 31:1577–1583. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
McKenna A, Hanna M, Banks E, Sivachenko A,
Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly
M and DePristo MA: The genome analysis toolkit: A MapReduce
framework for analyzing next-generation DNA sequencing data. Genome
Res. 20:1297–1303. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cibulskis K, Lawrence MS, Carter SL,
Sivachenko A, Jaffe D, Sougnez C, Gabriel S, Meyerson M, Lander ES
and Getz G: Sensitive detection of somatic point mutations in
impure and heterogeneous cancer samples. Nat Biotechnol.
31:213–219. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li J, Lupat R, Amarasinghe KC, Thompson
ER, Doyle MA, Ryland GL, Tothill RW, Halgamuge SK, Campbell IG and
Gorringe KL: CONTRA: Copy number analysis for targeted
resequencing. Bioinformatics. 28:1307–1313. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Campbell JD, Alexandrov A, Kim J, Wala J,
Berger AH, Pedamallu CS, Shukla SA, Guo G, Brooks AN, Murray BA, et
al: Distinct patterns of somatic genome alterations in lung
adenocarcinomas and squamous cell carcinomas. Nat Genet.
48:607–616. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jamal-Hanjani M, Wilson GA, McGranahan N,
Birkbak NJ, Watkins TBK, Veeriah S, Shafi S, Johnson DH, Mitter R,
Rosenthal R, et al: Tracking the evolution of non-small cell lung
cancer. N Engl J Med. 376:2109–2121. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Thompson JC, Yee SS, Troxel AB, Savitch
SL, Fan R, Balli D, Lieberman DB, Morrissette JD, Evans TL, Bauml
J, et al: Detection of therapeutically targetable driver and
resistance mutations in lung cancer patients by next-generation
sequencing of cell-free circulating tumor DNA. Clin Cancer Res.
22:5772–5782. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nahar R, Zhai W, Zhang T, Takano A, Khng
AJ, Lee YY, Liu X, Lim CH, Koh TPT, Aung ZW, et al: Elucidating the
genomic architecture of Asian EGFR-mutant lung adenocarcinoma
through multi-region exome sequencing. Nat Commun. 9:2162018.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
VanderLaan PA, Rangachari D, Mockus SM,
Spotlow V, Reddi HV, Malcolm J, Huberman MS, Joseph LJ, Kobayashi
SS and Costa DB: Mutations in TP53, PIK3CA, PTEN and other genes in
EGFR mutated lung cancers: Correlation with clinical outcomes. Lung
Cancer. 106:17–21. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Molina-Vila MA, Bertran-Alamillo J, Gascó
A, Mayo-de-las-Casas C, Sánchez-Ronco M, Pujantell-Pastor L,
Bonanno L, Favaretto AG, Cardona AF, Vergnenègre A, et al:
Nondisruptive p53 mutations are associated with shorter survival in
patients with advanced non-small cell lung cancer. Clin Cancer Res.
20:4647–4659. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mascaux C, Iannino N, Martin B, Paesmans
M, Berghmans T, Dusart M, Haller A, Lothaire P, Meert AP, Noel S,
et al: The role of RAS oncogene in survival of patients with lung
cancer: A systematic review of the literature with meta-analysis.
Br J Cancer. 92:131–139. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rotow J and Bivona TG: Understanding and
targeting resistance mechanisms in NSCLC. Nat Rev Cancer.
17:637–658. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li X, Cai W, Yang G, Su C, Ren S, Zhao C,
Hu R, Chen X, Gao G, Guo Z, et al: Comprehensive analysis of
EGFR-mutant abundance and its effect on efficacy of EGFR TKIs in
advanced NSCLC with EGFR mutations. J Thorac Oncol. 12:1388–1397.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sholl LM, Aisner DL, Varella-Garcia M,
Berry LD, Dias-Santagata D, Wistuba II, Chen H, Fujimoto J, Kugler
K, Franklin WA, et al: Multi-institutional oncogenic driver
mutation analysis in lung adenocarcinoma: The lung cancer mutation
consortium experience. J Thorac Oncol. 10:768–777. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pujol JL, Cooper EH, Lehmann M, Purves DA,
Dan-Aouta M, Midander J, Godard P and Michel FB: Clinical
evaluation of serum tumor marker CA 242 in non-small cell lung
cancer. Br J Cancer. 67:1423–1429. 1993. View Article : Google Scholar : PubMed/NCBI
|
